Nicholas Smith retweeted
Whole-body Bacteriophage Distribution Characterized by a Physiologically based Pharmacokinetic Model biorxiv.org/content/10.1101/… #biorxiv_micrbio
Very happy to share the team's latest publication on combating highly resistant, NDM-harboring Gram-negatives.
Special thanks to all the co-authors who made this project possible!
journals.asm.org/doi/10.1128…
1
Super excited to be collaborating with this fantastic team of scientists on combating "hypermutating" bacteria in the fight against antibiotic resistant superbugs as a part of our new $4.0M grant from NIH/NIAID!
pharmacy.buffalo.edu/news-ev…
1
Nicholas Smith retweeted
Honored to receive an award during @UICPharm research day
Wouldn't be where I am today without the support of awesome mentors & collaborators, thank you #GLab @TheIDApprentice @PrecisionAbxLab @SmithNicholasM #AntiAntibioticResistanceClub
Super grateful for this fantastic collaboration with Kari Mergenhagen and Dr. David Z. D'Argenio to increase options for TDM @pharmidgirl5
accpjournals.onlinelibrary.w…
2
The Smith Lab is looking for a Postdoctoral Associate to build the next frontier of individualized dosing and to identify solutions to bacterial drug resistance.
Located in a fantastic and highly affordable city with a dynamic social scene. (Go Bills!) ubjobs.buffalo.edu/postings/…
Drug-Drug interactions? How about Bug-bug interactions?
Interesting to see changes in antibiotic effects depending on the presence of multiple organisms.
doi.org/10.1128/AAC.02414-20
Excited to be presenting our group's poster at this year's #IDWeek2020 Thanks to all for their collaboration!
Things that go Bump in the Night: Combating Klebsiella pneumoniae co-producing New Delhi metallo-beta-lactamase and Mobile Colistin Resistance cdmcd.co/5YG4rK
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial thelancet.com/journals/lanin…
1



